National Academies Press: OpenBook
« Previous: 8 Considering Next Steps
Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×

References

CDC (Centers for Disease Control and Prevention). 2009. About CDC. http://www.cdc.gov/about/stateofcdc/html/2008/AboutTopic.htm (accessed August 2, 2010).

FDA (Food and Drug Administration). 2009. Remarks of Margaret A. Hamburg, M.D., Commissioner of Food and Drugs at AAAS: The Future of Personalized Medicine, October 26, 2009. http://www.fda.gov/NewsEvents/Speeches/ucm191356.htm (accessed May 24, 2010).

FDA. 2010a. President’s Fiscal Year 2011 Budget Request for the FDA. http://www.fda.gov/NewsEvents/Testimony/ucm204399.htm (accessed June 4, 2010).

FDA. 2010b. Science Board to the Food and Drug Administration. http://www.fda.gov (accessed March 15, 2010).

FDA. 2010c. NIH and FDA Announce Collaborative Initiative to Fast-Track Innovations to the Public. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201706.htm (accessed May 24, 2010).

FDA. 2010d. Fast Track, Accelerated Approval and Priority Review. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm (accessed May 24, 2010).

FDA. 2010e. How Many People Are Employed by FDA and in What Areas Do They Work? http://www.fda.gov/AboutFDA/Transparency/Basics/ucm213161.htm (accessed August 5, 2010).

FDA. 2010f. FDA Beyond Our Borders. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm103036.htm (accessed August 5, 2010).

FDA Science Board. 2007. FDA Science and Mission at Risk. Rockville, MD: Report of the Subcommittee on Science and Technology.

FitzGerald, G. 2010. Regulatory Science and FDA. http://iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/2010-FEB-26/Microsoft%20PowerPoint%20%20FitzGerald-IOMFDA.ashx (accessed March 19, 2010).

GAO (Government Accountability Office). 2009. Medical Devices: FDA Should Take Steps to Ensure That High-Risk Device Types Are Approved Through the Most Stringent Premarket Review Process. GAO-09-190. Washington, DC: GAO.

Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×

Grossman, Steven. 2010. Top 10 Things That Hill Staff Need to Know About FDA. http://strengthenfda.org/2010/03/06/top-10-%E2%80%9Cthings-that-hill-staff-need-toknow-about-fda%E2%80%9D/ (accessed August 2, 2010).

Harrill, A. H., P. B. Watkins, S. Su, P. K. Ross, D. E. Harbourt, I. M. Stylianou, G. A. Boorman, M. W. Russo, R. S. Sackler, S. C. Harris, and P. C. Smith, R. Tennant, M. Bogue, K. Paigen, C. Harris, T. Contractor, T. Wiltshire, I. Rusyn, and D. W. Threadgill. 2009. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Research 19(9):1507–1515.

HHS (Department of Health and Human Services). 2010. Advancing the Health, Safety, and Well-Being of Our People. http://www.hhs.gov/asrt/ob/docbudget/2011budget inbrief.pdf (accessed December 21, 2010).

IOM (Institute of Medicine). 2007. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academies Press.

IOM. 2008. Emerging Safety Science. Washington, DC: The National Academies Press.

IOTF (Interagency Oncology Task Force). 2010. Joint Fellowship Program. http://iotftraining.nci.nih.gov/ (accessed May 26, 2010).

Kim, S. 2010. Model of Data Sharing in IIRIS/COE. http://iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/2010-FEB-26/Microsoft%20PowerPoint%20-%20Kim-IOM-2010-02-26%20FDA%20Centers%20of%20Excellence.ashx (accessed March 19, 2010).

NCI (National Cancer Institute). 2010. Clinical Trials Cooperative Group Program. http://www.cancer.gov/cancertopics/factsheet/NCI/clinical-trials-cooperative-group (accessed May 26, 2010).

NIH (National Institutes of Health). 2010. NIH and FDA Announce Collaborative Initiative to Fast-Track Innovations to the Public. http://www.nih.gov/news/health/feb2010/od24.htm (accessed August 5, 2010).

Nordenberg, D. 2010. Centers of Excellence in Regulatory Science Network. http://iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/2010-FEB-26/Microsoft%20PowerPoint%20%20NordenbergIOM%20Ctrs%20of%20Excellence%20Feb%2026%202010%20v24.ashx (accessed March 19, 2010).

OMOP (Observational Medical Outcomes Partnership). 2010. About Us. http://omop.fnih.org (accessed March 26, 2010).

Peck, C. 2010. Centers of Excellence (COEs) in Regulatory and Information Science: Accelerating Development of Innovative Products and Ensuring the Public’s Health. Unpublished paper submitted to IOM Forum on Drug Discovery, Development, and Translation.

Research!America. 2010. America Speaks. http://www.researchamerica.org/uploads/AmericaSpeaksV10.pdf (accessed March 19, 2010).

Roses, A. 2010. IOM 26 Feb 2010 FDA Centers of Excellence for Regulatory Science. http://iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/2010-FEB-26/Microsoft%20PowerPoint%20-%20Roses.pdf (accessed August 9, 2010).

Roses, A. D., M. W. Lutz, H. Amrine-Madsen, A. M. Saunders, D. G. Crenshaw, S. S. Sundseth, M. J. Huentelman, K. A. Welsh-Bohmer, and E. M. Reiman. 2009. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s Disease. Pharmacogenomics J. doi: 10.1038/tpj.2009.69.

The Scientist. 2009. More Regulatory Science—FDA Chief. http://www.the-scientist.com/blog/display/55984/ (accessed May 24, 2010).

Sigal, E. 2010. Opportunities for Enhancing Regulatory Science: A Blueprint to Benefit Patients. http://iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/2010-FEB26/Microsoft%20PowerPoint%20-%20Sigal-IOM%20Reg%20Science%20FINAL.ashx (accessed March 19, 2010).

Skarke, C., and G. A. FitzGerald. 2010. Training translators for smart drug discovery. Science Translational Medicine 2(26):26cm12.

Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×

USC (University of Southern California). 2010. Frequently Asked Questions—Regarding the Program. http://regulatory.usc.edu/help.aspx#q1 (accessed May 24, 2010).

Wagner, J. A., E. C. Wright, M. M. Ennis, M. Prince, J. Kochan, D. J. R. Nunez, B. Schneider, M. D. Wang, Y. Chen, S. Ghosh, B. J. Musser, and M. T. Vassileva. 2009. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clinical Pharmacology and Therapeutics 86(6):619-625.

White House. 2010. Making Moves for a Healthier Generation. http://www.whitehouse.gov/blog/2010/02/09/making-moves-a-healthier-generation (accessed June 4, 2010).

Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×

This page intentionally left blank.

Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×
Page 53
Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×
Page 54
Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×
Page 55
Suggested Citation:"References." Institute of Medicine. 2011. Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12968.
×
Page 56
Next: Appendix A: Agenda »
Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA's science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the state of regulatory science and to consider approaches for enhancing it.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!